INTRODUCTION
Chronic myelogenous leukaemia (CML) is a clonal disorder caused by the neoplastic transformation of a pluripotent haematopoietic stem cell (reviewed in [1] ). The hallmark of CML is the presence of the Philadelphia chromosome (also known as Phh), the result of a t(9 ; 22)(q34 ; q11) reciprocal translocation and subsequent fusion of the c-ABL proto-oncogene on chromosome 9 with the BCR gene on chromosome 22 [2] [3] [4] [5] [6] .
There are two major forms of the BCR\ABL fusion gene resulting from the joining of ABL exon 2 to different exons of the BCR gene. One fusion involves breaks within the major breakpoint cluster region (M-bcr) of BCR, which includes introns 13 and 14, and leads to the production of an 8.5 kb transcript coding for a 210 kDa protein (p210) [7] . In CML, most translocations involve the M-bcr of BCR. The other fusion gene is the result of breaks within the first intron of BCR (the minor breakpoint cluster region, m-bcr) and leads to the expression of a smaller 7.5 kb transcript that codes for a 190 kDa (p190) protein [8] (Figure 1 ). Other, less common, fusions have also been reported (reviewed in [9] ). Whereas both BCR\ABL fusion proteins display activated tyrosine kinase activity, the p190 form, more frequently associated with acute lymphoblastic leukaemia, is more potently transforming. The p190 BCR\ABL fusion more efficiently transforms cells in culture [10] [11] [12] . p190 BCR\ABL transgenic mice develop leukaemia with a higher penetrance and shorter latency than p210 BCR\ABL transgenic mice [13] [14] [15] [16] [17] [18] . Also, p190 BCR\ABL transgenic mice always develop acute leukaemia while some p210 BCR\ABL mice develop a myelodysplastic syndrome resembling human CML [18] .
Generation of the p210-encoding BCR\ABL transcript from the Philadelphia chromosome requires splicing of the 3h-most BCR exon to ABL exon 2. This can involve the excision of greater than 200 kb of pre-mRNA, including ABL exons 1a and 1b [19] . Alternative splicing of the p210 BCR\ABL transcript has Abbreviations used : CML, chronic myelogenous leukaemia ; M-bcr, major breakpoint cluster region ; m-bcr, minor breakpoint cluster region ; RT, reverse transcriptase. 1 Present address : Ottawa Regional Cancer Centre, 3rd Floor, 501 Smyth Road, Ottawa, Ontario, Canada K1H 8L6. 2 To whom correspondence should be addressed, at Ontario Cancer Institute, Princess Margaret Hospital, Rm. 9-622, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9 (e-mail s.kamel.reid!utoronto.ca).
basic BCR minigene expressed exon-inclusive transcripts only, insertion of genomic DNA spanning ABL exon 2 induced exonskipping but only when expressed in the CML cell lines K562 and EM3. In this study we localized the required sequence element to ABL exon 2 itself. These results mimic the splicing phenotype displayed by most CML patients. We propose a model where a trans-factor present in some CML cells interacts with ABL exon 2 pre-mRNA to promote skipping of upstream BCR exons.
Key words : alternative, CML, minigene, splicing. also been reported in which alternative BCR exons 1a or 1b are utilized [20] , as both BCR promoters can be active. ABL exon 2 can also alternatively splice to BCR exon 13 by skipping exon 14 [21] . In both cases the result is a variant p210-encoding transcript produced from a Philadelphia chromosome with a break in the M-bcr. Recently, we, and others, have reported the co-expression of both the p210-and p190-encoding BCR\ABL transcripts in CML patient samples [22] [23] [24] . We believe this co-expression to be the result of alternative splicing from a single BCR\ABL allele [24] .
Alternative splicing serves as a means by which a single gene can code for multiple proteins and provides an important level of post-transcriptional regulation. Control of alternative splicing is generally mediated through the interaction of trans-acting splice regulators with cis-elements present within the nascent premRNA transcript [25, 26] . In some cases it is the presence or absence of particular splice-regulatory proteins [27, 28] , while in others it may be the relative abundance of multiple spliceregulatory proteins that determines the pattern of splicing [29] . Aberrant splicing has been associated with several pathologies including cancer [30] [31] [32] [33] and amyotrophic lateral sclerosis [34] . Alternative splicing of fusion transcripts associated with cancer has been reported in desmoplastic small round cell tumour [35] , T-cell acute lymphoblastic leukaemia [36, 37] and acute myeloid leukaemia [38, 39] . Alternative splicing of fusion transcripts in these malignancies could be the result either of the juxtaposition of sequences not normally present within the same transcript or of the expression of splice-regulatory factors that direct this alternative splicing, or a combination of both.
In this study we have set out to develop a model for the alternative splicing of BCR\ABL detected in CML patient cells. We have constructed BCR\ABL minigenes that displayed exonskipping only when expressed in CML cells. This exon-skipping was dependent on the presence of ABL sequences, which we have localized to ABL exon 2. We propose a model where transacting
Figure 1 Genomic organization of the BCR/ABL fusion gene at the Philadelphia chromosome translocation breakpoint
The p210-encoding transcript is produced from chromosomes with a break in the M-bcr while the p190-encoding transcript is usually produced from chromosomes with a break in the m-bcr. It is possible to produce a p190-encoding transcript from a Philadelphia chromosome with an M-bcr junction through alternative splicing. Such an exon-skipping event would remove as much as 300 kb of pre-mRNA.
factors present in some CML cells interact with ABL exon 2 premRNA to promote exon-skipping. This leads to expression of the more potently transforming p190 isoform.
MATERIALS AND METHODS

Detection of BCR/ABL and BCR transcripts
Peripheral blood or bone-marrow samples from patients with a referring diagnosis of CML were obtained for molecular studies as part of a diagnostic workup. Normal peripheral blood leucocytes were obtained from healthy volunteers. Red cells were lysed and total RNA was extracted from the white-cell pellet, as well as from control cell lines, using the Qiagen RNeasy kit according to the manufacturer's instructions. Total RNA (500 ng) was subjected to reverse transcription using random hexamers and Moloney murine leukaemia virus reverse transcriptase (RT). Following this, 10 % of the cDNA was used in a nested PCR using primers specific for BCR exons 1 (GCA GCT CCA ATG AGA ACC TC) and 15 (CCC AAA GGA ATC CAC CTC CA followed by ATC CAC CTC CAG GGT GCA GT) or BCR exon 1 (ACC ATC GTG GGC GTC CGC AAG A followed by AGA TCT GGC CCA ACG ATG GCG AGG GC) and ABL exon 2 (TGA TTA TAG CCT AAG ACC CGG A followed by ATC TCC ACT GGC CAC AAA ATG CAT ACA). External amplifications were heated to 94 mC for 5 min and then subjected to 26 cycles of 94 mC for 30 s, 63 mC for 30 s and 72 mC for 15 s followed by a 5 min soak at 72 mC. Prior to the nested PCR, 10 µl of the external reactions were diluted to 1 ml with H # O. Internal reactions were heated to 94 mC for 5 min and then subjected to 30 cycles of 94 mC for 30 s, 65 mC for 30 s and 72 mC for 15 s followed by a 5 min soak at 72 mC in a Thermal Cycler (Perkin Elmer, Rexdale, ON, Canada). Products were resolved on 1 % agarose gels.
Cell lines
The CML cell lines K562 and EM3 were maintained in RPMI 1640 (10 % fetal bovine serum), as was the histiocytic lymphoma line U937. The adherent cell lines, 293T (simian virus 40 large TAg-transformed human kidney) and CV1 (African Green monkey kidney), were maintained in α-modified Eagle's medium (10 % fetal bovine serum).
Construction of BCR and BCR/ABL minigenes
In order to construct the basic BCR minigene three fragments were inserted into a pBlueScript (pBS ; Stratagene) backbone in a step-wise fashion (see Figure 2 ). First a 4218 bp genomic BCR SacI\EcoRI fragment containing the entire BCR promoter [40] [41] [42] , as well as the first exon of BCR and the first 1500 bp of intron 1 was cloned into pBS. Next, a 2606 bp BglII\BamHI fragment of genomic DNA spanning BCR exons 12 and 13 was blunted and cloned into the EcoRV site of pBS downstream from the BCR exon 1 fragment. This BCR exon 12\13 fragment did not include the transcriptional repressor located within intron 13 of BCR [42] . For the final step PCR primers were designed to amplify a product from the eukaryotic expression vector pSG5 (Stratagene) consisting of rabbit β-globin intron, 3h splice acceptor site and exon fused to the 3h-untranslated region, and poly(A + ) signal of polyoma large T antigen. These primers were designed to include a KpnI site, which was used to clone the product into the polylinker KpnI site present in the pBS portion of the minigene construct. A 1359 bp genomic fragment spanning ABL exon 2 was then amplified from human genomic DNA using primers appended with ClaI sites. This fragment was cloned into pBS for manipulation and subcloned into the unique ClaI site downstream of BCR exon 13 to create the BCR\ABL minigene.
Generation of ABL mutants
The 3h splice site of ABL intron 1 was replaced with the 3h splice site of BCR intron 11 using the PCR ( Figure 2 ). Two products were amplified from the cloned ABL genomic fragment described above using primers specific for sequences flanking the 3h splice site, which were appended with overlapping sequences derived from the 3h splice site of BCR intron 11 (GTT GGA AAA GAG GTG CAC CAA TTG GTA GTT TTA TTC TCA GAA GCA), a vector (pBS)-specific primer to amplify the upstream intron (GTG CAC CTC TTT TCC AAC CTC CCA GAA GCC CTT CAG CGG CCA GTA) and a vector (pBS)-specific primer to amplify ABL exon 2 plus down-Exon-skipping in BCR/ABL
Figure 2 Schematic diagram of BCR minigene, 3h splice sites and ABL genomic inserts
(A) Basic BCR minigene consisting of the BCR promoter, exon 1 and 1500 bp of intron 1 linked to a 2606 bp genomic fragment spanning BCR exons 12 and 13 (B12 and B13) and a rabbit β-globin terminal exon with the large T antigen poly(A + ) signal. ABL genomic fragments were inserted at the unique Cla I site (*). Minigene transcripts were detected by RT-PCR. Primer sites are shown (arrows). (B) Alignment of 3h splice sites upstream of ABL exon 2 in BCR/ABL pre-mRNA. Those of the upstream BCR introns have shorter polypyrimidine tracts with more interruptions than that of ABL intron 1, which has an unusually long and uninterrupted polypyrimidine tract. Upper-case letters indicate pyrimidines and lower-case letters indicate purines. (C) Three versions of the ABL genomic insert used in this study. The 3h splice site of ABL intron 1 was replaced with the BCR intron 11 3h splice site (m ; see B) to generate the splice-site-switched insert while ABL exon 2 was replaced with BCR exon 13 to generate the exon-switched insert. wt, wild-type.
stream intron (partially overlapping BCR intron 11 sequences are underlined). These two products were then isolated and allowed to anneal at the overlapping BCR intron 11 sequences with which they were appended and extended to blunt ends with Pfu polymerase. A fused splice-site switched product was then amplified using Pfu polymerase and the flanking vector (pBS)-specific primers. Similarly an exon-switched mutant was generated from three PCR products, one corresponding to BCR exon 13 (with primers GTT TCA GAA GCT TCT CC TG and CTT CCT TAT TGA TGG TCA GC), one derived from ABL intron 1 which was amplified with a BCR exon 13-appended primer [GAT GTC AGG GAG AAG CTT CTG AAA CCT GGA AGA GAA AGG GGG GAA and a vector (pBS)-specific primer ; BCR exon 13 sequence underlined], and a fragment derived from ABL intron 2 amplified with a BCR exon 13-appended primer [ATT CCG CTG ACC ATC AAT AAG GAA GGT AAA AGG GTT GTG GGC AGC and a vector (pBS)-specific primer ; BCR exon 13 sequences underlined]. These three products were allowed to anneal at the overlapping BCR exon 13 sequences, extended to blunt ends and a fused exon-switched product was amplified using pBSspecific primers and Pfu polymerase. Both mutant ABL fragments were flanked by ClaI sites that were used to insert them into the BCR minigene, creating splice-site-switched BCR\ ABL and exon-switched BCR\ABL minigenes, respectively.
Transfections and RT-PCR
Transient transfections of 293T and CV1 cells were performed using Qiagen Superfect reagent according to the manufacturer's instructions. Transient transfections of K562, EM3 and U937 cells were performed using Qiagen Effectene reagent according to the manufacturer's instructions. Briefly, 10 µg of minigene plasmid was mixed with the appropriate transfection reagent and either incubated with 10& cultured cells for 3 h and then replaced with fresh culture medium (Superfect transfections) or left in the medium (Effectene transfections). Transfection efficiencies of 30 % (293T and CV1 cells with Superfect) and 5 % (K562 and U937 with Effectene) were achieved with other constructs expressing green fluorescent protein under these conditions (results not shown). Post-transfection (18 h) total RNA was collected using the Qiagen RNeasy kit. Total RNA (500 ng) was reverse transcribed using oligo(dT) primers and Moloney murine leukaemia virus RT : 10 % of the resulting cDNA was subjected to nested PCR using primers specific to BCR exon 1 (GCA GCT CCA ATG AGA ACC TC followed by ACA GTC CTT CGA CAG CAG CA) and rabbit β-globin (GCA CAA TAA CCA GCA CGT TG followed by ATA ACC AGC ACG TTG CCC AG) to detect minigene-specific transcripts.
RESULTS
Exon-skipping is confined to the translocated allele of BCR
We investigated whether co-expressing leukaemic cells displayed a gross dysregulation of splicing that dysregulated the splicing of both alleles of BCR or whether the alternative splicing was confined to BCR exons in the context of the fusion transcript. The splicing of the germ-line allele of BCR was assessed by RT-PCR using primers specific for BCR exons 1 and 15 ( Figure 3) . As BCR exon 15 is not translocated to the Philadelphia chromosome this primer pair detects transcripts derived from the germline allele only. By RT-PCR we were able to detect multiple isoforms of BCR\ABL in both CML patient samples and the CML cell line K562 but failed to detect alternatively spliced forms of BCR in any of the same samples (Figure 3 ). These data
Figure 3 Detection of BCR/ABL and BCR transcripts by RT-PCR
(A) Germ-line BCR transcripts were detected using primers specific for BCR exons 1 and 15 (flanking checked region representing BCR exons 2-14). Alternatively spliced forms were not detected in any sample (lanes are as listed for B). (B) BCR/ABL transcripts were detected using primers specific for BCR exon 1 and ABL exon 2. p210-encoding transcripts (upper arrow) were detected in all five CML patient samples (lanes [1] [2] [3] [4] [5] and in the CML cell line K562 (lanes 6). Four CML patients (lanes 1, 2, 3 and 5) displayed a p190-encoding transcript as well (lower arrow). One CML patient in this group expressed a different, alternatively spliced form (*, middle arrow, lane 4, BCR exons 1, 9, 10, 11, 12, 13, ABL exon 2). Only the p190-encoding transcript was detected in SupB15 (Phh-positive acute lymphoblastic leukaemia cell line, lanes 7). BCR/ABL transcripts were not detected in normal peripheral blood leucocytes (lanes 8-10) . R, reagent control.
indicate that alternative splicing was confined to those BCR exons found in the context of the BCR\ABL fusion transcript.
Construction of BCR and BCR/ABL minigenes
We hypothesized that the juxtaposition of ABL sequences and BCR exons induces exon-skipping. To test this hypothesis we constructed a BCR minigene into which various ABL genomic fragments were inserted (Figure 2) . In order to detect exonskipping events similar to those detected in CML patient samples we constructed an unusually large minigene with 4 or 5 exons (three from BCR and one from rabbit β-globin, plus or minus an ABL exon). The expression of the minigene transcript, which included those BCR exons present on the classic Philadelphia chromosome minus exons 2-11, was driven by the BCR promoter [40] [41] [42] rather than a strong viral promoter in order to mimic the expression level of the BCR\ABL fusion gene. The transcriptional repressor reported to lie within BCR intron 13 [42] was not included. As the BCR promoter used in our minigene constructs was relatively weak, minigene transcripts were detected using nested RT-PCR primers specific for BCR exon 1 and the terminal rabbit β-globin exon. Since the alternative splice-forms detected in patient samples were the results of various BCR exons being joined to ABL exon 2, we decided initially to generate a BCR\ABL minigene containing ABL exon 2. A genomic fragment spanning ABL exon 2 was amplified from human genomic DNA and inserted downstream of BCR exon 13 in the sense or antisense orientation (Figure 2 ).
Alternative splicing is dependent on ABL sequences and a CML cell type
When our first minigene constructs were transfected into K562 cells (CML) and 293T (Phh-negative) cells we were able to detect alternatively spliced forms only in the CML cell line K562 (Figure 4) . Also, exon-skipping was only detected when ABL sequences were inserted in the sense orientation. Alternatively spliced forms were isolated and sequenced for identification. Three isoforms ; BCR1\12\13\globin, BCR1\12\globin and BCR1\ABL2\globin, were detected in transfected K562 cells (Figures 4 and 5) as well as the CML cell line EM3 (results not shown) but were not seen in 293T (Figure 4 ), U937 ( Figure 5 ) or CV1 cells (results not shown).
Figure 4 RT-PCR detection of minigene transcripts
Exonic sequences are required for induction of exon-skipping
Mutant versions of the genomic fragment encompassing c-ABL exon 2 were generated and inserted into the BCR minigene in order to identify the minimal ABL sequences required to induce exon-skipping. The 3h splice site of ABL intron 1 has an unusually long and uninterrupted polypyrimidine tract [21] . To determine whether this splice site played a role in alternative splicing we replaced it with the consensus-like 3h splice site from BCR intron 11 using PCR to generate 3h splice-site switch BCR\ABL ( Figure  2) . When a BCR\ABL minigene containing this mutant ABL insert was transfected into K562 cells, alternative splicing was still detected (Figure 5 ), indicating that this unusual ABL intron 1 splice site was not required for the induction of alternative splicing. The resulting PCR products were subcloned and sequenced to confirm the presence of both the BCR1\12\13\ Figure 5 Exon-skipping requires ABL exon 2 BCR/ABL minigenes with mutant ABL genomic inserts were transfected into the CML cell line K562 and the non-CML cell line U937. Minigene transcripts were detected by RT-PCR. In both cell lines the BCR minigene produced an exon-inclusive A-type transcript (lanes 1). The insertion of an ABL exon 2-spanning genomic fragment (lanes 2) led to the production of an exon-inclusive B-type transcript in each cell line (upper band) while the K562 cells produced alternatively spliced transcripts as well (upper arrow indicates C-type and D-type transcripts ; lower arrow indicates E-type transcript). Replacement of the unusual 3h splice site in the ABL genomic insert failed to alter this alternative splicing seen in K562 cells (lanes 3). Replacement of ABL exon 2 with BCR exon 13 abolished exon-skipping in K562 cells (lanes 4) leading to the production of F-type transcripts in both cell lines. Replacement of ABL exon 2 with BCR exon 13 in the antisense direction led to the production of A-type transcripts (lanes 5). M, mock transfection ; R, reagent control. Symbols for the different exons are as for Figure 4. globin and BCR1\ABL2\globin splice forms (results not shown). We also replaced ABL exon 2 with BCR exon 13 (flanked by ABL introns 1 and 2) to determine whether ABL exon 2 itself was required for the induction of exon-skipping in the minigene transcript (Figure 2) . When a BCR\ABL minigene containing this insert (exon-switched BCR\ABL) was transfected into K562 cells we were no longer able to detect alternatively spliced forms of the minigene transcript ( Figure 5) . Again, the resulting PCR product was sequenced to confirm its identity (results not shown). This result indicates that ABL exon 2 is required for the induction of alternative splicing in the context of the BCR\ABL minigene transcript.
DISCUSSION
Alternative splicing of the BCR/ABL transcript is induced by ABL exon 2
We have previously reported the detection of p190-and p210-encoding BCR\ABL transcripts in CML patient samples. We
Figure 6 Proposed model for the alternative splicing of the BCR/ABL transcript
We propose that the internal BCR exons are spliced together prior to the excision of the large first introns of BCR and ABL respectively. This may occur through the formation of two large internal ' exons ' when exons 2-8 and 9-14 are joined due to their relative proximity. We propose further that a trans-acting factor active in some CML cells interacts with ABL exon 2 RNA to facilitate the joining of BCR exon 1 and ABL exon 2 generating a p190-encoding fusion transcript.
hypothesized that this co-expression was due to alternative splicing of a BCR\ABL pre-mRNA as these patients displayed a single Philadelphia chromosome per cell and because we could detect additional alternatively spliced forms in some samples [24] . It is interesting to note that in reports of the rare variant e19\a2 BCR\ABL translocation (creating a BCR exon 19-ABL exon 2 junction), alternatively spliced forms that resulted from exon-skipping of upstream BCR exons were detected as well [43, 44] , implying that ABL exon 2 can affect the splicing of various upstream BCR exons. In this study we have examined the mechanism underlying this exon-skipping phenomenon. We failed to detect alternative splicing of the wild-type BCR transcript produced from the germ-line allele of BCR expressed in both patient samples and the CML cell lines K562 and EM3. This observation implied that the alternative splicing of those BCR exons present on the Philadelphia chromosome was affected by their context within the BCR\ABL fusion transcript. To study the effect of ABL sequences on the splicing of BCR exons we constructed a series of BCR and BCR\ABL minigenes. Through the use of this model we determined that the juxtaposition of ABL exon 2 with upstream BCR exons induced exon-skipping but only when the minigene was expressed in the CML cell lines K562 and EM3 (results not shown). Thus our minigene constructs serve as a model for the alternative splicing phenomenon that we observe in many of our CML patients.
Alternative splicing of several genes has been associated previously with tumourigenesis [30] [31] [32] [33] [35] [36] [37] [38] [39] . In some cases this leads to the production of isoforms that may have differing transforming abilities [35] or may affect the response of the malignant cells to environmental signals [30] , whereas in other cases the expression of a particular alternatively spliced form may have prognostic value [31] . As well, it has become clear that alternative splicing plays an important role in the regulation of apoptosis as different isoforms of some mediators have opposing influences on this pathway [45] [46] [47] . This study is the first to examine the mechanism underlying the production of a cancerassociated splice form. Whether the production of a particular splice form in malignant cells is an acquired phenotype that provides a malignant clone with a particular advantage remains to be demonstrated. In the case of BCR\ABL it is easy to envisage that the production of the more highly transforming p190 fusion would confer a selective advantage on a subclone that expressed this splice form. In line with this, our previous study found that co-expressing CML patients had higher whiteblood-cell and blast-cell counts than did patients who expressed the p210-encoding transcript [24] .
The exon-skipping phenotype conferred by the juxtaposition of ABL exon 2 with upstream BCR exons detected in CML patient samples, and modelled by our minigene constructs, is unusual. Most cases of exon-skipping that have been studied to date have dealt with the variable inclusion of a particular exon containing or flanked by elements which regulated its inclusion [48] [49] [50] . In this case the required element lies in an exon that is included and affects the variable inclusion of upstream exons. This exon-skipping could be viewed as a competition for splicing to BCR exon 1. This exonic element may prove to be a splicing enhancer that plays a role in the physiological splicing of the c-ABL transcript where alternative first exons are utilized [21] . The putative trans-acting factor that interacts with ABL exon 2 may play a role in the regulation of exon joining rather than exon definition.
The genomic structure of the BCR\ABL fusion gene consists of two large introns, intron 1 and the gap between the last BCR exon and ABL exon 2 ( Figure 6 ). We propose a model in which the internal BCR exons are spliced together prior to the removal of these two large introns. In this model the exclusion of these two large ' exons ' would lead to the production of the p190 transcript ; an event that could be promoted by the interaction of some trans-acting factor with ABL exon 2, either by slowing the joining of ABL exon 2 to the proximal BCR exon and\or by promoting the interaction of the BCR exon 1-bound splicing factors with ABL exon 2-bound splicing factors (Figure 6 ). In the context of our minigene transcripts these intron sizes are much reduced, which may explain why the alternatively spliced forms detected do not exactly reflect those seen in patient samples, as we detect forms that lack ABL exon 2 as well as the expected BCR1\ABL2 alternatively spliced form. This model may serve to detect those factors that play a role in the regulation of exon joining, rather than exon definition. Also, the use of large minigene constructs like those in these studies may facilitate our understanding of the mechanisms by which splicing may be regulated over longer distances.
In this study we have developed a model for the alternative splicing of the BCR\ABL fusion transcript previously detected in CML patient samples [22] [23] [24] . These studies determined that this exon-skipping is induced by the juxtaposition of ABL exon 2 with upstream BCR exons in the context of a fusion transcript. In addition, this alternative splicing is cell-type-dependent and may require the interaction of a hypothetical trans-acting factor with a cis-element present within ABL exon 2. We do not know what role these elements have in regulating the splicing of c-ABL, where exon 2 is joined to either of two upstream exons, 1a or 1b [21] . Further analysis of this model will help to elucidate the mechanism underlying co-expression of p190-and p210-encoding transcripts in CML.
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